Compile Data Set for Download or QSAR
Report error Found 61 Enz. Inhib. hit(s) with all data for entry = 12352
TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697107(US20240309005, Compound 22)
Affinity DataIC50: 0.272nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697142(US20240309005, Compound 84)
Affinity DataIC50: 0.508nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697119(US20240309005, Compound 38)
Affinity DataIC50: 0.508nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697114(US20240309005, Compound 29)
Affinity DataIC50: 0.595nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697143(US20240309005, Compound 85)
Affinity DataIC50: 0.600nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697136(US20240309005, Compound 73)
Affinity DataIC50: 0.631nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697094(US20240309005, Compound 9)
Affinity DataIC50: 0.730nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697146(US20240309005, Compound 154)
Affinity DataIC50: 0.980nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697139(US20240309005, Compound 78)
Affinity DataIC50: 1.04nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697120(US20240309005, Compound 42)
Affinity DataIC50: 1.08nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697145(US20240309005, Compound 96)
Affinity DataIC50: 1.09nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697112(US20240309005, Compound 27)
Affinity DataIC50: 1.20nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697141(US20240309005, Compound 80)
Affinity DataIC50: 1.23nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697132(US20240309005, Compound 68)
Affinity DataIC50: 1.27nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697113(US20240309005, Compound 28)
Affinity DataIC50: 1.32nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697103(US20240309005, Compound 18)
Affinity DataIC50: 1.35nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697133(US20240309005, Compound 69)
Affinity DataIC50: 1.39nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697121(US20240309005, Compound 45)
Affinity DataIC50: 1.47nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697144(US20240309005, Compound 86)
Affinity DataIC50: 1.60nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697095(US20240309005, Compound 10)
Affinity DataIC50: 1.61nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697093(US20240309005, Compound 8)
Affinity DataIC50: 1.64nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697110(US20240309005, Compound 25)
Affinity DataIC50: 1.70nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697102(US20240309005, Compound 17)
Affinity DataIC50: 1.80nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697124(US20240309005, Compound 48)
Affinity DataIC50: 1.82nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697115(US20240309005, Compound 30)
Affinity DataIC50: 2.05nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697096(US20240309005, Compound 11)
Affinity DataIC50: 2.41nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697122(US20240309005, Compound 46)
Affinity DataIC50: 2.44nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697118(US20240309005, Compound 34)
Affinity DataIC50: 2.47nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697127(US20240309005, Compound 53)
Affinity DataIC50: 2.96nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697126(US20240309005, Compound 50)
Affinity DataIC50: 3.04nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697140(US20240309005, Compound 79)
Affinity DataIC50: 3.06nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697109(US20240309005, Compound 24)
Affinity DataIC50: 3.70nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697131(US20240309005, Compound 66)
Affinity DataIC50: 3.83nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697111(US20240309005, Compound 26)
Affinity DataIC50: 3.90nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697128(US20240309005, Compound 56)
Affinity DataIC50: 5.43nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697117(US20240309005, Compound 33)
Affinity DataIC50: 5.75nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697130(US20240309005, Compound 63)
Affinity DataIC50: 5.97nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697123(US20240309005, Compound 47)
Affinity DataIC50: 5.97nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697129(US20240309005, Compound 58)
Affinity DataIC50: 6.12nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697100(US20240309005, Compound 15)
Affinity DataIC50: 8.66nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697125(US20240309005, Compound 49)
Affinity DataIC50: 8.68nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697116(US20240309005, Compound 32)
Affinity DataIC50: 9.46nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697098(US20240309005, Compound 13)
Affinity DataIC50: 11.7nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697097(US20240309005, Compound 12)
Affinity DataIC50: 16.9nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697104(US20240309005, Compound 19)
Affinity DataIC50: 17.5nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697108(US20240309005, Compound 23)
Affinity DataIC50: 21.7nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697105(US20240309005, Compound 20)
Affinity DataIC50: 52.7nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697092(US20240309005, Compound 7)
Affinity DataIC50: 67.4nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697106(US20240309005, Compound 21)
Affinity DataIC50: 68.8nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

TargetSerine/threonine-protein kinase Sgk1(Human)
Thryv Therapeutics

US Patent
LigandPNGBDBM697137(US20240309005, Compound 74)
Affinity DataIC50: 349nMAssay Description:The compounds were tested for SGK-1 activity by measuring the ability of the compound to inhibit the transfer of phosphate from ATP by the isolated e...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
1/16/2025
Entry Details
US Patent

Displayed 1 to 50 (of 61 total ) | Next | Last >>
Jump to: